Combined use of WEB2170 and HBO therapy can reduce ischemia and reperfusion injury to the skeletal muscle in a rabbit model.
Ischemia/reperfusion injury is regarded as the main cause of failure in revascularization of limbs and transfer of free flaps in the so called nonreflow phenomenon. This type of damage is caused by the production of free radicals, above all, of neutrophils that release great quantities of extracellular superoxide through the action of a membrane enzyme. In our study we used 40 white rabbits. Rabbit rectus femoris muscle is perfused by a single artery and vein and is therefore a valuable model for study of ischemia-induced reperfusion injury of skeletal muscle. The objective of this study was to individualize a valid method of protection for the muscle from damage by ischemia-induced reperfusion injury. We have tested the effectiveness of WEB2170, a PAF antagonist, of hyperbaric oxygen therapy one (HBO), and of combined employment of WEB2170 and HBO. The results show that both PAF and HBO play important protective roles against damage from ischemia/reperfusion injury, and that the combined employment of both therapies has a synergistic effect. We propose therefore a new therapeutic protocol for the prevention of damage resulting from ischemia/reperfusion injury with the simultaneous employment of this PAF and HBO.
Riccio
Michele
M
Hand Surgery and Microsurgery Unit, Plastic and Reconstructive Surgery Department, Ancona University School of Medicine, Ancona, Italy. michiriccio@libero.it
Pangrazi
Pier Paolo
PP
Campodonico
Andrea
A
Scalise
A
A
Marchesini
A
A
Talevi
D
D
Carboni
A
A
Bertani
C
C
Bertani
Aldo
A
Mazzanti
L
L
D000818:Animals; D001381:Azepines / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D006931:Hyperbaric Oxygenation; D018482:Muscle, Skeletal / Q000098:blood supply; D009195:Peroxidase / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011817:Rabbits; D015427:Reperfusion Injury / Q000517:prevention & control*; D014230:Triazoles / Q000627:therapeutic use*
D001381:Azepines; D010975:Platelet Aggregation Inhibitors; D014230:Triazoles; C063964:bepafant; D009195:Peroxidase